Collegium Pharmaceutical Inc. (COLL) exhibits 59.3% gross margins and 85.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 3.0x enterprise multiple and 4.8% implied options volatility.
Sustained 59.3% gross profitability converts into 23.0% operating margin and 85.0% ROIC, outpacing sector cost of capital.
ROIC: 85.0% // GM: 59.3%YoY revenue trajectory of +23.6% paired with 2.80% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +23.6% // FCF YLD: 2.80%Altman Z-Score of 1.27 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.27 // F-SCORE: 7/9Trading at 12.4x trailing P/E (10.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 12.4x // EV/EBITDA: 3.0xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $24.03 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 8.1% net margins.
NET MARGIN: 8.1% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for COLL & activate live FRED threshold breach alerts.